HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical and radiobiologic evaluation of radiation dosage in radiotherapy of vaginal cancer].

Abstract
The investigation has been concerned with the results of combined (distant + contact) treatment and contact low-, medium-, and high-dosage radiotherapy alone in 133 patients with primary tumors of the vagina (VT). Time-dose-fractionation (TDF), cumulative radiation effect (CRE) and linear-quadratic (LQ) ("extrapolated dose of response") models were employed to evaluate the response of normal tissue. There was no correlation between survival in VT patients treated with radiation only and the tolerance limits for connective tissue estimated using TDF, CRE and LQ models being exceeded. The incidence of late-onset radiation injuries rose significantly by 20% (p < 0.05) when the TDF- and CRE-based limits of tolerance were exceeded. The LQ model had no similar predictive value. The TDF model proved more convenient in radiobiological assessment of different patterns of total focal dose fractionation, selection of similarly effective modalities as well as in prediction of late-onset radiation injury.
AuthorsS V Kanaev, V G Turkevich
JournalVoprosy onkologii (Vopr Onkol) Vol. 42 Issue 6 Pg. 44-7 ( 1996) ISSN: 0507-3758 [Print] Russia (Federation)
Vernacular TitleKliniko-radiobiologicheskaia otsenka velichiny luchevykh nagruzok pri radioterapii raka vlagalishcha.
PMID9123901 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Topics
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Neoplasm Staging
  • Radiation Injuries (etiology)
  • Radiotherapy (adverse effects)
  • Radiotherapy Dosage
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • Vaginal Neoplasms (pathology, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: